Access to regulatory data from the European Medicines Agency: the times they are a-changingby Beate Wieseler, Natalie McGauran, Michaela F Kerekes, Thomas Kaiser
a milestone for data transparency in clinical research is within reach- it is hoped this is not unnecessarily delayed.
Data sharing: reaching consensus.by Jimmy Whitworth
Jimmy Whitworth calls for a more sustainable and palatable pathway be will to build consensus and to create a broad coalition.
Sharing research data to improve public healthby Walport, M, Brest, P.
Mark Walport and Paul Brest argues that we need to ensure that research outputs are used to maximise knowledge and potential health benefits
Whose data set is it anyway? Sharing raw data from randomized trialsby Andrew Vickers
In this paper, Andrew Vickers argues that attitudes towards data sharing in the clinical trial community need to rethought, drastically
A systematic review of barriers to data sharing in public healthby Willem G van Panhuis, Proma Paul, Claudia Emerson, John Grefenstette, Richard Wilder, Abraham J Herbst, David Heymann, Donald S Burke
This study looks at the challneges of data sharing globally.
Secure use of individual patient data from clinical trialsby Patrick Vallance, Iain Chalmers
Publishing the results of all clinical trials, whoever funds them, is required for ethical, scientific, economic, and societal reasons
Prepublication data sharingby Toronto International Data Release Workshop Authors
Rapid release of prepublication data has served the field of genomics well. Attendees at a workshop in Toronto recommend extending the practice to other biological data sets.
Sharing health data: developing country perspectivesby Viroj Tangcharoensathien, Jirawan Boonperm, Pongpisut Jongudomsuk
Sharing data is not only about the technical dimension such as data management, repositories and libraries; developing countries are concerned about factors that impede data sharing, in particular, fairness
Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical databy Strech D, Littmann J
Comparing potential commercial interests with seven specifications of relevant public interest reveals the lack of proportionality inherent in the current practices of EMA and NICE.
The double-edged sword of open access to research databy John A. Spertus
John A. Spertus suggests that there needs to be some consideration about the practicalities of data sharing- in how it is shared, investment, and ensuring that data are appropriately analyzed
The delay in sharing research data is costing livesby Josh Sommer
This article argues that scientists need to feel greater urgency to share their findings quickly, and they need additional avenues to facilitate this process.
Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industryby So D, Joly Y, Knoppers BM
This paper summarises major developments in clinical trial transparency between January and June 2013 and analyses the composition of datasets released by GlaxoSmithKline.
Increasing the accessibility of databy Smith, G. D.
This article looks at the benefits of data sharing, and argues for increasing the accessibility of data
Introduction: data sharing and disclosure limitation techniquesby Sieber, J. E.
This article details the procedures and requirements for researchers in sharing data from clinical trials.
Characteristics desired in clinical data warehouse for biomedical researchby Soo-Yong Shin, Woo Sung Kim, Jae-Ho Lee
This article proposes some key characteristics needed in a clinical data warehouses for biomedical research
Sharing research data to improve public health: a perspective from the global southby Osman Sankoh, Carel IJsselmuiden
This article asks the question: how do we achieve fair trade in the sharing of clinical data?
The International Stroke Trial databaseby Peter AG Sandercock, Maciej Niewada, Anna Członkowska, the International Stroke Trial Collaborative Group
We aimed to make individual patient data from the International Stroke Trial (IST), available for public use, to facilitate the planning of future trials and to permit additional secondary analyses.
Ushering in a new era of open science through data sharing: the wall must come downby Joseph S. Ross, Harlan M. Krumholz
This article argues against selective publication and for a clear view of the totality of evidence relevant to many research questions and clinical decisions.
Promoting transparency in pharmaceutical industry-sponsored researchby Ross JS, Gross CP, Krumholz HM
Policies that promote transparency in the clinical trial research process, through improved and expanded disclosure of investigator contributions and funding, comprehensive publicly available trial registration, and independent analysis of clinical trial data analysis may address these subversive practices by improving accountability among industry and investigators.
Clinical trial data as a public goodby Marc A. Rodwin, John D. Abramson
Lack of access to detailed information about clinical trials can undermine the integrity of medical knowledge.